Johan Albrecht
Analyst · Piper Jaffray. Your line is open
Thank you, Fried. I’ll start with a brief review of our consolidated revenue on slide six. For clarity, I’d like to remind you that when we refer to sales in our presentation, this means revenues plus deferred revenues. Also, as we noted in our year-end call, with an increasing portion of our revenue from our Materialise Software and Materialise Manufacturing segments, the financial results are influenced by the seasonality of those businesses. For the first quarter, we generated a 14% quarter-over-quarter increase in revenue, with increases in all three of our segments. Materialise Software accounted for 28% of our revenue in quarter one, Materialise Medical for 32%, and Materialise Manufacturing for 40%. We continue to execute on two of our most important strategies – to grow the contribution of software revenue and to increase end part manufacturing. Across all three of our segments, revenue from software sales and end parts contributed 8% of total revenue as compared to 73% in last year’s period. The remaining 20% was generated through the production of prototypes. Moving to slight seven, you can see our consolidated adjusted EBITDA numbers for the first quarter. As Peter mentioned earlier, consolidated adjusted EBITDA rose 550 basis points, swinging from a small loss of €288,000 in the 2015 period to €1.135 million this quarter. Our adjusted EBITDA margin improved from a negative 1.2% to plus 4.3%. These improvements reflect three factors. First, continued shift of revenue mix to industrial and medical software licenses; second, an improvement in Manufacturing’s gross margin, primarily as a result of a continued efficiency and material cost improvement; and third, a moderate increase of 5.4% in operational expenses compared to our 14.2% of revenue growth. Slide eight summarizes the results of our Materialise Software segment. There, revenue grew 22%, fueled by a 25% increase of recurring license revenue. We also generated strong growth in sales from OEMs, which was up 13% over last year’s period. And the segment EBITDA grew 25%, outpacing our revenue growth, and EBITDA margin increased from 36.2% in last year’s first quarter to 37.2% in this year’s period. Turning to slide nine, you will see that total revenue in our Materialise Medical segment grew 10% for the quarter. Medical software sales grew 4% over last year’s first quarter, revenues representing 36% of the total Medical segment. Direct sales of complex surgery devices increased 27% over last year’s first quarter and sales from our medical collaboration partners were also up, rising by 12%. EBITDA for the Medical segment this quarter was €530,000 negative as compared to minus €746,000 in prior-year period. EBITDA margin improved by 330 basis points to minus 6.2%. Now, let’s turn to slide ten for a few details on the first quarter performance of the Materialise Manufacturing segment. Their revenue rose 13%, with sales of end parts jumping 62% over last year’s first quarter and accounting for 48% of the segment sales, up from 34% last year. We added four printers, bringing the company's total to 142. EBITDA rose almost 300 basis points to €257,000 from a small loss of €40,000 for the same period last year. The margin increased to 2.4% this quarter as compared to minus 0.4% in the 2015 period. Slide 11 provides the highlights of our income statement for the first quarter. Gross profit increased almost 19% year-over-year and gross margin increased to 59.9% from 57.7%. The increases reflect a continued shift of our revenue mix towards both industrial and medical software licenses, as well as an improvement of the gross margin of our Materialise Manufacturing segment. In total, R&D, sales and marketing, and G&A spending rose by 5% over the prior-year period, a much smaller percentage than in many periods during last year when we were staffing up after our IPO and expanding our sales and marketing efforts worldwide. On a quarter-over-quarter basis, sales and marketing decreased slightly, while R&D remained relatively stable. Our G&A expenses rose, but most of this increase reflected the managerial structure and support we have been implementing within our sales and marketing and R&D groups. In fact, a number of employees with mixed roles within these groups have evolved into more managerial and/or administrative roles. And the costs as well as certain other expenses are not categorized into G&A. Other income net decreased by €0.5 million to €1.3 million. Net other operating income consists primarily of withholding tax exemptions for qualifying researchers, development grants, partial funding of R&D projects, and currency exchange on purchase and sales transactions. The decrease was due primarily to the variance in the currency exchange loss, which resulted in a small loss of €48,000 compared to a gain that we booked of €0.5 million in the last year’s period. We posted an operating loss of €989,000 compared to an operating loss of €2.05 million for the same quarter of last year, an improvement of €1.1 million. Net financial result was negative by €0.7 million compared to a profit of €1.5 million the same period last year, almost entirely reflecting the variance in currency exchange rates, primarily on the portion of the company’s IPO proceeds held in US dollars. This is a reported, but mostly unrealized, exchange loss. Net loss for the first quarter of 2016 was minus €3.151 million compared to a net loss of €888,000 for the same period in the prior year, as a result of an increase of income tax by €1 million primarily due to the usage of a deferred tax asset and a decrease of our net financial result by €2.2 million, again all non-recurring and mostly non-cash elements, which were partially offset by substantial improvement of our operating profit by €1.1 million. Now, please turn to slide 12 for a recap of balance sheet and cash flow highlights. Our balance sheet remains strong, with minimum debt accounting for only 15% of total liabilities and equity at quarter-end. We ended the quarter with cash and cash equivalents, including held-to-maturity investments, of €49.4 million compared to €50.7 million as of December 31, 2015 and €61 million as of end 2014. Total deferred income amounted €18.2 million compared to €16.6 million at year-end 2015. The deferred annual software sales and maintenance contracts rose to €14 million from €12.2 million 12 months ago. Capital expenditures amounted €1.6 million compared to €3.1 million for the first quarter of 2015, in which period was included also non-recurring capacity expansion investments. Cash flow from operations increased €1.4 million from €800,000 last year. With that overview, I will turn the call back to Peter to discuss our operational highlights.